Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology.


Journal Article

This selection from the NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC) focuses on targeted therapies and immunotherapies for metastatic NSCLC, because therapeutic recommendations are rapidly changing for metastatic disease. For example, new recommendations were added for atezolizumab, ceritinib, osimertinib, and pembrolizumab for the 2017 updates.

Full Text

Duke Authors

Cited Authors

  • Ettinger, DS; Wood, DE; Aisner, DL; Akerley, W; Bauman, J; Chirieac, LR; D'Amico, TA; DeCamp, MM; Dilling, TJ; Dobelbower, M; Doebele, RC; Govindan, R; Gubens, MA; Hennon, M; Horn, L; Komaki, R; Lackner, RP; Lanuti, M; Leal, TA; Leisch, LJ; Lilenbaum, R; Lin, J; Loo, BW; Martins, R; Otterson, GA; Reckamp, K; Riely, GJ; Schild, SE; Shapiro, TA; Stevenson, J; Swanson, SJ; Tauer, K; Yang, SC; Gregory, K; Hughes, M

Published Date

  • April 2017

Published In

Volume / Issue

  • 15 / 4

Start / End Page

  • 504 - 535

PubMed ID

  • 28404761

Pubmed Central ID

  • 28404761

Electronic International Standard Serial Number (EISSN)

  • 1540-1413

Digital Object Identifier (DOI)

  • 10.6004/jnccn.2017.0050


  • eng

Conference Location

  • United States